- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00517686
Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT) (FIT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Project Description: We propose a cluster randomized trial intervention involving eight or more medical facilities of Kaiser Permanente Northern California (KP) and more than 65,000 patients at high risk for CVD. At intervention facilities, patient-level information obtained from KP's electronic health record on the need for treatment intensification (for systolic blood pressure, LDL-c, and A1c) and on recent medication adherence are added to a population management database and fed back through software currently used by staff working with primary care providers. Staff at control facilities continue to use the same population management database and software but only receive information on risk factor levels and selected medications.
Specific Aims:
- Evaluate the effectiveness of measurement and feedback of treatment intensification information in patients at high risk of CVD for improving rates of treatment intensification and for reducing levels of poorly controlled systolic blood pressure, LDL-c, and A1c.
- Evaluate the impact of the intervention, compared with current practice, on total numbers of patient contacts, outpatient visits, and costs of care in relation to improvements in risk factor control.
- Evaluate the effect of this innovation on physician and staff perceptions of the value (effectiveness and efficiency) of the population management program for high-risk patients.
Relevance: If this translational study shows that feedback of information on treatment intensification leads to higher rates of intensification and improved risk factor control, this finding will have shown a population-level use of health information technology for improving clinical quality and will also have validated treatment intensification as a metric of clinical quality.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Oakland, California, United States, 94612
- Kaiser Permanente - Division of Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Among the randomized medical facilities, we will study a population that is drawn from the PHASE registry and includes patients with at least one of the following:
- Diabetes, coronary artery disease; congestive heart failure; stroke/tia; peripheral artery disease; chronic kidney disease; hypertension; or hyperlipidemia
- PHASE patients must be in poor control for at least one CVD risk factor and meet study criteria for needing treatment intensification at some point during the 6-month period.
Exclusion Criteria:
- All patients eligible for the study will be included in the analyses
- There will be no exclusions based on clinical or other criteria.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
|
This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
|
|
No Intervention: 2
Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Tightly-linked processes (i.e., was treatment intensified more frequently) measured in the 3 months after initial reporting of need for intensification; and mean levels of intermediate outcomes (SBP, LDL-c, and A1c), measured for all study population.
Time Frame: 3 months; 1 year
|
3 months; 1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportions in control for each risk factor; treatment intensification and risk factor improvements in subgroups; and efficiency in terms of patient contacts, visits and costs per unit improvement in risk factor control.
Time Frame: 3 months; 1 year
|
3 months; 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joe V Selby, MD, MPH, Kaiser Permenante, Division of Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RFA-HS-07-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease (CVD) Risk Factors
-
Oregon Health and Science UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingCardiovascular Disease (CVD) Risk FactorsUnited States
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
University Hospital, AkershusUniversity of Oslo; Oslo University HospitalEnrolling by invitationGender Incongruence | Cardiovascular Disease (CVD) Risk FactorsNorway
-
Universidade Federal de Santa CatarinaCompletedRisk Factors Cardiovascular DiseaseBrazil
-
University Hospital, BordeauxCompletedCardiovascular Disease Risk FactorsFrance
-
Lübomira SpassovaCentre Hospitalier du LuxembourgCompletedCardiovascular Diseases | Stroke | Cerebrovascular Diseases | CVD Risk Factors
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Penn State UniversityOcean Spray Cranberries, Inc.CompletedCardiovascular Disease Risk FactorsUnited States
-
The University of Hong KongHealth and Medical Research FundCompleted
-
Mayo ClinicCompletedCardiovascular Disease Risk FactorsUnited States
Clinical Trials on Information feedback intervention
-
Karolinska InstitutetWithdrawnSubstance Use Disorders | Benzodiazepine Dependence | Benzodiazepine AbuseSweden
-
US Department of Veterans AffairsCompleted
-
Universidad PanamericanaUniversidad de la Salud - UNISA; IMSS-Bienestar; Secretaría de Educación, Ciencia...Not yet recruitingEpisiotomy | Episiotomy Wound | Episiotomy Extended by Laceration | Episiotomy Infection
-
Boston Medical CenterBoston University; National Institute on Drug Abuse (NIDA); RTI InternationalCompletedDrug Abuse | Drug Usage | Drug DependenceUnited States
-
University of MiamiCompletedDiagnoses DiseaseUnited States
-
University of HoustonNational Institute on Drug Abuse (NIDA)CompletedAnxiety Disorders | Anxiety | Tobacco Dependence | Smoking, Tobacco | Smoking, CigaretteUnited States
-
National Institute of Allergy and Infectious Diseases...UnknownHIV Infections
-
Oslo Metropolitan UniversityThe Research Council of Norway; St. Olavs Hospital; Netherlands Instititute for... and other collaboratorsCompleted
-
NextSense, Inc.TerminatedSleep | Sleep Quality | Technology | Sleepiness, DaytimeUnited States